Path to market: PRR has a path to market – it can follow Dendreon (DNDN US, not rated) which is in the US market with Provenge, an immunotherapy prostate cancer
recurrence vaccine. As a fast follower, we believe PRR’s manufacturing technology has the potential to BETTER THAN DNDN’s."
From the Nomura Report.
dndn q3 result, page-3
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.5¢ | $1.317M | 3.935M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73996 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 836970 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |